[Effect of Tongxinluo on endothelial function and hypersensitive C-reactive protein in acute coronary syndrome patients undergoing percutaneous coronary intervention]
- PMID: 19587440
[Effect of Tongxinluo on endothelial function and hypersensitive C-reactive protein in acute coronary syndrome patients undergoing percutaneous coronary intervention]
Abstract
Objective: To determine the effect of Tongxinluo on the endothelial function and hypersensitive C-reactive protein (hs-CRP) in acute coronary syndrome patients undergoing percutaneous coronary intervention(PCI).
Methods: Thirty-three patients with unstable angina pectoris and 6 patients with acute myocardial infarction who underwent PCI for stenotic lesions of the coronary artery were enrolled. The patients were randomly assigned to a conventional group (n = 19) which took routine treatment or a tongxinluo group (n = 20) which took Tongxinluo(4 capsules once, 3 times per day) at the base of routine treatment after PCI. Nitric oxide synthase (NOS), nitric oxide (NO), endothelium-dependent vasodilation which was evaluated in the brachial artery flow mediated diameter(FMD) and hs-CRP were measured before the PCI and 24 hours and 3 months after the PCI. The correlation between NO and hs-CRP was analyzed.
Results: NOS, NO, and FMD in the 2 groups 24 hours after the PCI were significantly lower than those before the PCI(P < 0.05), but hs- CRP obviously increased (P < 0.05). NOS, NO, and FMD 3 months after the PCI in the 2 groups were significantly higher than those before the PCI (P < 0.05 or P < 0.01), but hs-CRP obviously decreased (P < 0.01).All indexes mentioned above in the Tongxinluo group showed greater changes than those of the conventional group(P < 0.05). NO was negatively correlated with hs-CRP (r = -0.3219, P<0.01).
Conclusion: Tongxinluo capsules have obvious beneficial effect on endothelial function and anti-inflammation in acute coronary syndrome patients undergoing PCI, by directly acting on the endothelium and indirectly inhibiting inflammation.
Similar articles
-
[Effect of Xinmaitong capsule on serum matrix metalloproteinases-9, high sensitive C-reactive protein levels in patients with acute coronary syndrome].Zhongguo Zhong Yao Za Zhi. 2007 May;32(9):850-2. Zhongguo Zhong Yao Za Zhi. 2007. PMID: 17639992 Clinical Trial. Chinese.
-
[Effect of danhong injection on ET-1, sP-sel, and hs-CRP in patients with acute coronary syndrome undergoing percutaneous coronary intervention].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Jan;31(1):11-4. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011. PMID: 21434335 Clinical Trial. Chinese.
-
[Effect of tetramethylpyrazine on platelet activation and vascular endothelial function in patients with acute coronary syndrome undergoing percutaneous coronary intervention].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Dec;27(12):1078-81. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007. PMID: 18198639 Clinical Trial. Chinese.
-
Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels.Ann Med. 2000 Nov;32(8):515-8. doi: 10.3109/07853890008998830. Ann Med. 2000. PMID: 11127928 Review.
-
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.Crit Care Nurse. 2010 Oct;30(5):45-54. doi: 10.4037/ccn2010384. Crit Care Nurse. 2010. PMID: 20889512 Review. No abstract available.
Cited by
-
Tongxinluo Attenuates Myocardiac Fibrosis after Acute Myocardial Infarction in Rats via Inhibition of Endothelial-to-Mesenchymal Transition.Biomed Res Int. 2019 Jun 16;2019:6595437. doi: 10.1155/2019/6595437. eCollection 2019. Biomed Res Int. 2019. PMID: 31317035 Free PMC article.
-
Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Pharmacol. 2018 Aug 3;9:830. doi: 10.3389/fphar.2018.00830. eCollection 2018. Front Pharmacol. 2018. PMID: 30123126 Free PMC article.
-
Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention.Cochrane Database Syst Rev. 2015 May 21;2015(5):CD010237. doi: 10.1002/14651858.CD010237.pub2. Cochrane Database Syst Rev. 2015. PMID: 25994229 Free PMC article.
-
Efficacy and Safety of Tongxinluo Capsule as Adjunctive Treatment for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Pharmacol. 2021 Oct 11;12:742978. doi: 10.3389/fphar.2021.742978. eCollection 2021. Front Pharmacol. 2021. PMID: 34707500 Free PMC article. Review.
-
Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications.Heliyon. 2024 Jun 21;10(13):e33309. doi: 10.1016/j.heliyon.2024.e33309. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39040283 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous